Snapshot from Aug 02, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / PROCEPT BioRobotics securities class action
Regulatory class action

PROCEPT BioRobotics securities class action

Analysis based on 6 articles · First reported Jul 30, 2026 · Last updated Aug 01, 2026

Sentiment
-60
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit and underlying disclosures of excess inventory and declining sales have negatively impacted PROCEPT's stock price, which fell over 18% after the Q4 2025 earnings report. The legal action adds regulatory and litigation risk, potentially affecting investor confidence and the company's market valuation.

Medical Devices
Event Summary

Pomerantz LLP filed a class action lawsuit against PROCEPT BioRobotics Corporation (Nasdaq: PRCT) alleging securities fraud and unlawful business practices. The suit claims that the company and certain officers/directors made misleading statements regarding handpiece sales and inventory. Specifically, PROCEPT reported quarterly handpiece sales that missed guidance, reduced annual guidance, and ultimately revealed cumulative excess field inventory of over 10,000 units. The company's stock price fell significantly following each earnings announcement. Investors have until September 22, 2026, to seek lead plaintiff status.

Key Actions
100 Pomerantz LLP filed class action PROCEPT BioRobotics
90 PROCEPT BioRobotics disclosed excess field inventory
85 PROCEPT BioRobotics missed sales guidance
Entities Involved
stock
PROCEPT BioRobotics
PROCEPT is the defendant in the class action and the subject of the alleged securities fraud. The company's stock price fell significantly following each earnings disclosure, and it now faces legal and reputational challenges.
Importance 100.0 Sentiment -80.0
priv
Pomerantz LLP
Pomerantz LLP filed the class action lawsuit against PROCEPT, representing investors. The firm is a prominent securities class action litigator and stands to gain from a successful case.
Importance 70.0 Sentiment 20.0
per
Kevin Waters
Kevin Waters, CFO of PROCEPT, provided guidance and disclosures that were part of the alleged misleading statements. He is named as an officer involved in the securities fraud allegations.
Importance 40.0 Sentiment -50.0
per
Larry L. Wood
Larry L. Wood, CEO, admitted to inventory management issues and provided guidance that contributed to the alleged misrepresentations. He is named as an officer in the lawsuit.
Importance 40.0 Sentiment -50.0
per
Reza Zadno
Reza Zadno, former CEO, announced the elimination of the Chief Commercial Officer role, which was part of the events leading to the lawsuit. He is named as a former officer in the allegations.
Importance 30.0 Sentiment -50.0
exch
Nasdaq
Nasdaq is the exchange where PROCEPT is listed. The event does not directly impact Nasdaq, but the stock's performance is tracked on this exchange.
Importance 10.0 Sentiment 0.0
Relationships
Pomerantz LLP related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.